15 October 2026
EMADOC-1829012207-74127
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (initial authorisation)

Neuzafy

filgrastim

On 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Neuzafy, intended for the treatment of neutropenia and the mobilisation of peripheral blood progenitor cells (PBPCs).

The applicant for this medicinal product is CuraTeQ Biologics (Malta) Limited.

Neuzafy will be available as 30 MU/0.5 ml and 48 MU/0.5 ml solution for injection/infusion. The active substance of Neuzafy is filgrastim, an immunostimulant, colony stimulating factor (ATC code: L03AA02). Filgrastim is a recombinant granulocyte colony-stimulating factor (G-CSF), a type of haematopoietic growth factor. By binding to the G-CSF receptor, filgrastim stimulates the production and differentiation of mature and functionally active neutrophils from bone marrow precursor cells.

Neuzafy is a biosimilar medicinal product. It is highly similar to the reference product Neupogen (filgrastim), which has been authorised in various EU countries. Data show that Neuzafy has comparable quality, safety and efficacy to Neupogen (filgrastim). More information on biosimilar medicines can be found here.

The full indication is:

> Neuzafy is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
>
> The safety and efficacy of Neuzafy are similar in adults and children receiving cytotoxic chemotherapy.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2026. Reproduction is authorised provided the source is acknowledged.

Neuzafy is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).

In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 10^9/L, and a history of severe or recurrent infections, long term administration of Neuzafy is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.

Neuzafy is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1 x 10^9/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.

Neuzafy should be prescribed and given by physicians experienced in oncology and haematology.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.